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A b s t r a c t
Alzheimer’s disease neuropathologic change (ADNC) in the form of β-amyloid (Aβ) deposits is important not only in 
the pathogenesis of Alzheimer’s disease (AD) and Down’s syndrome (DS) but also as a ‘co-pathology’ in disorders such 
as dementia with Lewy bodies (DLB), corticobasal degeneration (CBD), and chronic traumatic encephalopathy (CTE). 
To compare cortical and hippocampal degeneration in different disorders, the spatial patterns of the diffuse, primi-
tive, and classic Aβ deposits were studied in regions of frontal and temporal cortex in five neurodegenerative disor-
ders, viz. AD, DS, DLB, CBD, and CTE using spatial pattern analysis. In all disorders, the Aβ deposits were clustered 
and in a proportion of brain regions, the clusters were regularly distributed parallel to the tissue boundary. Cluster 
dimensions in the cortex, measured parallel to the pia mater, were frequently in the range 400-800 µm suggesting 
a spatial association with the cortico-cortical pathways. Differences were also observed among disorders, the diffuse 
Aβ deposits being more frequently distributed in regular clusters in AD while cluster sizes of the diffuse and primitive 
deposits were significantly smaller in CTE. The data suggest considerable similarities in the spatial patterns of Aβ 
deposits in different disorders, regardless of the clinical or pathological setting, which suggests that the spread of Aβ 
via neuro-anatomical pathways may be common to several disorders. 
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Introduction
Alzheimer’s disease neuropathologic change 
(ADNC) in the form of β-amyloid (Aβ) deposits [26,35] 
occurs in a variety of neurodegenerative disorders. 
Aβ is a  ‘signature’ pathological lesion of Alzhei-
mer’s disease (AD) [19] and also plays a significant 
role in the pathology of Down’s syndrome (DS) 
[19,30,36,45]. In addition, Aβ deposits have been 
recorded as a ‘co-pathology’ in many other neurode-
generative disorders including dementia with Lewy 
bodies (DLB) [6], Parkinson’s disease (PD) [38], Pick’s 
disease (PiD) [38], corticobasal degeneration (CBD) 
[38], amyotrophic lateral sclerosis (ALS) [22], pro-
gressive supranuclear palsy (PSP) [38], and chronic 
traumatic encephalopathy (CTE) [31].
Aβ peptides are generated via β- and γ-secretase 
cleaving of amyloid precursor protein (APP) result-
ing in the formation of aggregated protein deposits 
[21,25]. A number of distinct types of Aβ deposit have 
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been described but the majority are classifiable into 
three morphological groups [17]. First, diffuse depos-
its are 10-200 µm in diameter, irregular in shape with 
diffuse boundaries, and are lightly immunolabeled 
with antibodies raised against Aβ. Second, primitive 
deposits are 20-60 µm in diameter, well demarcat-
ed, more symmetrical in shape, and more strongly 
immunolabeled. Third, classic deposits are 20-100 µm 
and comprise a distinct central ‘core’ surrounded by 
a ‘corona’ of dystrophic neurites (DN). Previous stud-
ies suggest that in the cerebral cortex, Aβ deposits 
are distributed with a degree of clustering of depos-
its regularly distributed parallel to the pia mater [3]. 
Aβ deposits may occur in discreet clusters but more 
frequently there is a continuous variation in density 
parallel to the tissue boundary with a succession of 
relatively dense areas interspersed with less dense 
areas [3]. This pattern suggests a spatial association 
between the Aβ deposits and the degeneration of 
neuro-anatomical pathways such as the cortico-cor-
tical projections [16,23,37]. This spatial association 
may also be the result of the hypothesized ‘prion-like’ 
spread of Aβ via neuro-anatomical connections 
[20,43]. Hence, previous studies of Creutzfeldt-Jakob 
disease (CJD), in which propagation of prion protein 
(PrPsc) along neuro-anatomical pathways is well doc-
umented [10-12], deposits of PrPsc are also clustered 
in the cerebral cortex, the clusters being regularly 
distributed parallel to the pia mater similar to the Aβ 
deposits in AD [7]. Hence, the presence of regularly 
distributed clusters of a pathology may be a marker 
of the spread of pathogenic proteins such as Aβ.
This study compared the spatial patterns of the 
Aβ deposits in five neurodegenerative disorders, viz. 
AD, DS, DLB, CBD, and CTE in which the Aβ peptide 
occurs in different clinical and pathological settings. 
Hence, Aβ is the primary pathological change in 
AD and DS, a co-pathology in CBD, whereas in DLB 
it may represent a  more intermediate condition. 
In addition, the disorders vary in their molecular 
pathology. Hence, AD, CBD, and CTE are tauopathies 
in which the deposition of abnormal forms of the 
microtubule-associated protein (MAP), tau in the 
form of neurofibrillary tangles (NFT) is a  defining 
feature [29]. By contrast, DLB is a synucleinopathy in 
which the synaptic protein α-synuclein is deposited 
in association with Lewy bodies (LB) [41]. In DS, Aβ 
results from triplication of the APP gene [39] while 
in CTE, Aβ deposition may be the result of repeti-
tive brain injury [18,28,42]. The principle objectives 
were to compare the spatial patterns of Aβ deposits 
among disorders and to determine whether there 
was evidence of the pathogenic spread of Aβ espe-
cially between adjacent cortical gyri such as the 
lateral occipito-temporal gyrus (LOT) and parahippo-
campal gyrus (PHG).
Material and methods
Cases
Demographic data and diagnostic criteria for the 
five disorders are listed in Table I. Informed consent 
was given for the removal of all brain tissue accord-
ing to the 1996 Declaration of Helsinki (as modified 
Edinburgh 2000). Case material for AD, DS, DLB, and 
CBD, in the form of microscope slides, was obtained 
from the Brain Bank, Department of Neuropathol-
ogy, Institute of Psychiatry, King’s College, London, 
UK. The primary criterion for the selection of the 
CBD, DLB, and CTE cases was the presence of suf-
Table I. Summary of demographic details, signature pathology, associated pathology, and diagnostic criteria 
in the disorders studied (n is the number of cases studied in each disorder)
Disorder, n Mean age, years (SD) M : F Signature lesion Additional pathology Diagnostic criteria
AD, 10 78.2 (8.3) 3 : 7 Aβ deposits NFT, GVC, EN NINCDS/ADRDA/CERAD
CBD, 4 62.5 (8.01) 2 : 2 NFT AP, GI, EN NIH-ORD
CTE, 6 71.6 (8.2) 6 : 0 NFT DN, DLG McKee et al. [32] 
DLB, 8 71.5 (3.40) 8 : 0 LB LN, LG CDLB
DS, 11 40.7 (4.03) 6 : 5 Aβ deposits NFT By karyotype
Disorders: AD – Alzheimer’s disease, DS – Down’s syndrome, CTE – chronic traumatic encephalopathy, DLB – dementia with Lewy bodies, CBD – corticobasal 
degeneration
Neuropathology: Aβ – β-amyloid, AP – astrocytic plaques, DN – dystrophic neurites, DLG – dot-like grains, EN – enlarged neurons, GI – glial inclusions, GVC – gra-
nulovacuolar change, LB – Lewy bodies, LG – Lewy grains, LN – Lewy neurites, NFT – neurofibrillary tangles
Diagnostic criteria: ‘National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders Association’ 
(NINCDS/ADRDA) [44], ‘Consortium to Establish a Registry of Alzheimer Disease’ (CERAD) criteria [34]; National Institute of Health-Office of rare disorders
(NIH-ORD); ‘Consortium on Dementia with Lewy bodies’ (CDLB)’ [33]
M – male, F – female, SD – standard deviation
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ficient densities of Aβ deposits consistent with the 
presence of ADNC [26,35]. By contrast, because of 
its scarcity, case material for CTE was obtained from 
Boston University’s CTE center (VA-BU-CLF Brain 
Bank) as a  series of scanned microscope images 
(Aperio Image-Scope Software, Leica Biosystems Inc. 
Buffalo Grove, IL, USA) [9]. All individuals with CTE 
had played American football, career durations being 
in the range of 11-24 years. In addition, all patients 
had suffered at least one traumatic episode result-
ing in concussion, some with accompanying loss of 
consciousness, the majority of cases having expe-
rienced multiple episodes of trauma during their 
careers. To determine whether the scanning of CTE 
slides affected the assessment of the spatial pattern 
compared with original microscope slides, a random 
sample of regions from the AD cases were stud-
ied both from microscope slides and from scanned 
images, no differences in the spatial pattern being 
detected.
Histological methods
Blocks of frontal (level of genu of corpus callo-
sum) and temporal cortex (at the level of the lateral 
geniculate nucleus) were taken from each case to 
study the superior frontal gyrus (SFG) (B8), lateral- 
occipito-temporal gyrus (LOT) (B36), parahippo-
campal gyrus (PHG) (B28), and hippocampus (HC), 
regions which have high densities of Aβ deposits in 
the disorders studied [3]. Tissue was fixed in 10% 
phosphate buffered formal-saline and embedded in 
paraffin wax. 7 µm coronal sections were immuno-
labeled with two rabbit polyclonal antibodies which 
recognize Aβ1−42: (1) Gift of Professor BH Anderton, 
Institute of Psychiatry, King’s College London, UK [40] 
and (2) END Millipore Billerica, MA, USA, (1 : 2000) 
[42] and counterstained with hematoxylin/eosin 
(H/E). Both antibodies identify Aβ1-42 and clearly 
revealed the diffuse, primitive, and classic subtypes 
of Aβ deposit which were identified in the sections 
using previously defined criteria [17]. 
Morphometric methods 
In each region where a  sufficient density of an 
Aβ deposit was present (at least 20 deposits along 
a  transect), spatial distribution was studied along 
each gyrus or CA sectors of the hippocampus using 
200 × 1000 µm contiguous sample fields; the short 
dimension of the field being aligned with the surface 
of the tissue boundary [1]. In the cerebral cortex, the 
sample fields were aligned with the surface of the 
pia mater, the longer dimension of the field includ-
ing layers I, II, and most of layer III; regions which 
contain the highest densities of Aβ deposits in the 
various disorders [3]. The sample fields were extend-
ed from the PHG/subiculum into the HC, the fields 
aligned first, with the alveus to sample sectors CA1 
to CA3 and second, using a guideline marked on the 
slide and which ceased approximately 400 µm from 
the dentate gyrus fascia, to sample sector CA4. 
The number of diffuse, primitive, and classic Aβ 
deposits was counted in each sample field. AD, DS, 
DLB, and CBD were examined using microscope 
slides at a magnification of ×100 using a micrometer 
grid with grid lines at intervals of 10 µm to define 
the sample field. By contrast, CTE was examined 
using the scanned images at ×100, the sample fields 
arranged contiguously and superimposed over the 
image using either the draw or rectangle options. 
The short edge of the sample field was orientated 
parallel with the pia mater and aligned with guide-
lines also marked on the section. Between 32 and 
64 sample fields were necessary to study each gyrus 
or CA sector depending on its length. The diffuse 
and primitive deposits were present in most brain 
regions studied but the classic deposits were pres-
ent in a more restricted number of regions. Hence, 
there are different numbers of analyses of the dif-
fuse, primitive, and classic Aβ deposits depending on 
their relative frequency. 
To estimate the intra- and inter-observer variabil-
ity in counts of Aβ deposits, five images selected at 
random were counted twice by the same observer one 
month apart and also by a second observer. Count- 
recount variability was tested using the ‘method 
of agreement’ described by Bland and Altman [13]. 
The essential feature of the Bland and Altman meth-
od is that for a particular histological feature, the dif-
ference between the two counts are subtracted for 
each case. The mean of these differences is known 
as the degree of ‘bias’ or ‘agreement’ and the stan-
dard deviation (SD) of the mean can be used to cal-
culate the ‘limits of agreement’ in which it would be 
expected that 95% of the differences between two 
successive counts would fall. For example, there was 
a good agreement between successive counts made 
by the same observer (intra-observer variability) of 
the diffuse Aβ deposits in Sector CA1 in a case of CTE. 
The mean difference between the two counts of the 
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diffuse deposits, averaged over the 32 sample fields 
was 0.08 lesions per 200 × 1000 mm sample field 
(SD = 0.48, limits of agreement –0.87-1.02. There 
was less agreement between different observers 
(inter-observer variability) with a mean difference of 
0.39 (SD = 0.48, limits of agreement –0.95 to +1.74. 
Similar results were obtained for the remaining four 
images. 
Data analysis 
The data were analyzed by spatial pattern anal-
ysis [2]; a  method which uses the variance/mean 
(V/M) ratio as a  measure of non-randomness and 
determines whether the deposits were distributed 
randomly (V/M = 1), regularly (V/M < 1) or in clus-
ters (V/M > 1) along the strip of cortex parallel to the 
pia mater. To perform the analysis, the V/M ratio is 
calculated from the data at various field sizes, e.g., 
200 × 1000 µm (the original field size) and then at 
400 × 1000 µm, 800 × 1000 µm etc., up to a size lim-
ited by the length of cortex sampled. Data for the 
larger field sizes are obtained by adding together 
successively the densities of deposits in adjacent 
sample fields. The V/M ratio is plotted against the 
increasing field size to reveal the spatial pattern. 
If the deposits are clustered, then the analysis indi-
cates whether the clusters themselves are randomly 
or regularly distributed and provides an estimate of 
the mean dimension of the clusters in a plane parallel 
to the pia mater. Regularly spaced clusters are indi-
cated by the V/M ratio increasing to a peak before 
declining at larger field sizes, the location of the 
peak corresponding to the mean dimension of the 
clusters. The frequency of cortical regions in which 
the size of regularly distributed clusters of deposits 
were in the range 400-800 µm, approximating to 
the dimension of the columns of neurons forming 
the cortico-cortical connections, was also deter-
mined [23]. Comparisons were made of the fre-
quencies of different types of spatial pattern of the 
Aβ deposits: (1) among deposit types within a dis-
order, (2) among disorders, and (3) the proportion 
of regular clusters 400-800 µm in diameter using 
c2 contingency table tests. Mean cluster sizes of Aβ 
deposits in different regions were compared using 
1-way analysis of variance (ANOVA) followed by the 
Tukey ‘honestly significant difference’ (THSD) post-
hoc test. 
Results
Figures 1-3 show variations in the density of Aβ 
deposits parallel to the pia mater in regions of the 
cerebral cortex in different disorders. Figure 1 shows 
the distribution of Aβ deposits in a case of AD, with 
the approximate positions of the clusters indicated, 
a number of clusters of deposits being evident main-
Fig. 1. Distribution of β-amyloid (Aβ) deposits 
along the superior frontal cortex in a case of Alz-
heimer’s disease. The approximate location of 
clusters of deposits along the cortex parallel to 
the pia mater mainly in the upper cortical layers 
are circled (Aβ immunostaining, H/E).
Fig. 2. Distribution of β-amyloid (Aβ) deposits 
along the lateral occipito-temporal gyrus (LOT) and 
parahippocampal gyrus (PHG) in a case of demen-
tia with Lewy bodies. Clusters of deposits (approx-
imate location circled) are present along the gyri 
affecting all layers (Aβ immunostaining, H/E).
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ly in the upper cortex and with a degree of regular 
spacing along the cortex. Figure 2 shows clustering 
of Aβ deposits in the PHG and LOT in a case of DLB 
with significantly fewer deposits in the HC while 
in Figure 3, the Aβ deposits are more continuously 
distributed along the PHG and LOT in a case of DS, 
and where it is virtually impossible to detect specific 
clusters.
Examples of the spatial pattern analysis are 
shown in Figure 4. First in AD, the primitive Aβ depos-
its in the PHG exhibited a V/M peak at a field size of 
200 µm indicating a regular distribution of clusters 
of deposits 200 µm in diameter parallel to the pia 
mater. Second in DS, the diffuse deposits in the PHG 
exhibited an increase in V/M with field size without 
reaching a  peak suggesting clustering of deposits 
on a  larger scale. Third in DLB, the classic deposits 
in the PHG exhibited a V/M peak at a field size of 
400 µm suggesting a regular distribution of clusters 
of deposits 400 µm in diameter. 
The frequencies of the various spatial pat-
terns of Aβ deposits summed over all cortical and 
hippocampal regions for each disorder are shown in 
Table II. The data suggested first, clustering of Aβ 
deposits was the most frequent spatial pattern pres-
ent in all disorders, uniform or random distributions 
being rare. Second, in a  significant proportion of 
regions, the clusters of Aβ deposits were regularly 
distributed parallel to the pia mater or alveus, this 
spatial pattern was present in all disorders varying 
in frequency from 63% of regions in AD to 39% in 
DS. Third, with the exception of CBD (c2 = 7.17, 6 DF, 
p > 0.05) and CTE (c2 = 2.59, 6 DF, p > 0.05), there were 
significant differences in spatial pattern exhibited 
by the three deposit subtypes, large-scale clustering 
Fig. 3. Distribution of β-amyloid (Aβ) deposits 
along the lateral occipito-temporal gyrus (LOT) 
and parahippocampal gyrus (PHG) in a  case of 
Down’s syndrome. Clustering of deposits is absent 
and a  more continuous distribution is present 
affecting all layers (Aβ immunostaining, H/E).
Fig. 4. Pattern analysis plots showing examples 
of the spatial patterns exhibited by β-amyloid 
deposits: AD – Alzheimer’s disease, DS – Down’s 
syndrome, DLB – dementia with Lewy bodies. Sig-
nificance of V/M peaks, arrows indicate p < 0.01. 
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Table II. Spatial patterns of the diffuse (D), primitive (P), and classic (C) β-amyloid (Aβ) deposits in the 
cortex and hippocampus (HC) in five neurodegenerative disorders (AD – Alzheimer’s disease, DS – Down’s 
syndrome, DLB – dementia with Lewy bodies, CBD – corticobasal degeneration, CTE – chronic traumatic 
encephalopathy); n – total number of brain regions sampled, R – random distribution, Reg – regular or 
uniform distribution. Data represent the number of brain areas in which a specific type of spatial pattern 
is present. Data in parentheses in column 7 represent the number of brain areas in which regularly spaced 
clusters were present within the size range 400-800 µm
Disorder Region Aβ type n R Reg Regular clusters 
(200–6400 µm)
Large clusters 
(> 6400 µm)
AD Cortex D 25 0 0 17 (8) 8
HC D 5 0 0 3 (1) 2
Cortex P 26 0 0 12 (6) 14
HC P 5 0 0 3 (2) 2
Cortex C 14 0 2 11 (10) 1
HC C 4 0 1 2 (0) 1
CBD Cortex D 7 2 1 1 (0) 3
HC D 1 0 0 0 1
Cortex P 5 1 0 3 (2) 1
HC P 1 0 0 1 (0) 0
Cortex C 5 0 0 3 (2) 2
HC C 1 0 0 1 (0) 0
CTE Cortex D 19 2 1 10 (4) 6
HC D 7 0 0 3 (1) 4
Cortex P 14 0 2 8 (4) 4
HC P 10 0 0 4 (3) 6
Cortex C 10 0 0 6 (2) 4
HC C 6 2 1 0 3
DLB Cortex D 13 0 0 3 (4) 10
HC D 4 0 0 2 (0) 2
Cortex P 10 0 1 6 (3) 3
HC P 4 0 0 2 (1) 2
Cortex C 10 1 1 8 (6) 0
HC C 3 0 0 2 (1) 1
DS Cortex D 13 0 0 3 (2) 10
HC D 11 0 0 4 (1) 7
Cortex P 12 1 0 5 (2) 6
HC P 10 0 0 3 (1) 7
Cortex C 10 2 3 5 (3) 0
HC C 5 0 0 4 (2) 1
Comparison of spatial patterns (c2 contingency tables):
(1)  Between cortex and HC: AD diffuse deposits c2 = 0.03 (1DF, p > 0.05), primitive deposits c2 = 0.06 (1DF, p > 0.05), classic deposits c2 = 1.45 (1DF, p > 0.05); 
CTE diffuse deposits c2 = 2.07 (3DF, p > 0.05), primitive deposits c2 = 3.15 (2DF, p > 0.05), classic deposits c2 = 8.68 (3DF, p < 0.05); DLB diffuse deposits 
c2 = 0.16 (1DF, p > 0.05), primitive deposits c2 = 0.77 (2DF, p > 0.05), classic deposits c2 = 3.99 (3DF, p > 0.05); DS diffuse deposits c2 = 0.07 (1DF, p > 0.05), 
primitive deposits c2 = 1.41 (2DF, p > 0.05), classic deposits c2 = 5.00 (3DF, p > 0.05)
(1)  Among deposit types within each disorder totaled over all regions: AD c2 = 17.12 (4DF, p < 0.05), DS c2 = 25.80 (6DF, p < 0.001), DLB c2 = 17.34 (6DF, p < 0.05), 
CBD c2 = 7.17 (6DF, p > 0.05), CTE c2 = 2.59 (6DF, p > 0.05)
(2)  Among disorders totaled over all regions: diffuse deposits c2 = 33.14 (12DF, p < 0.001), primitive deposits c2 = 16.83 (12DF, p > 0.05), classic deposits c2 = 15.70 
(12DF, p < 0.05)
(3) Proportion of regular distributed clusters 400-800 mm in diameter among disorders: diffuse deposits c2 = 4.23 (4DF, p > 0.05), primitive deposits c2 = 2.41 
(4DF, p > 0.05), classic deposits c2 = 6.18 (4DF, p > 0.05)
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of classic deposits being less frequently observed 
when compared to the diffuse and primitive depos-
its. Fourth, the primitive deposits (c2 = 16.83, 12 DF, 
p > 0.05) and classic deposits (c2 = 15.70, 12 DF, 
p < 0.05) exhibited no significant differences in 
spatial pattern among disorders. Fifth, the spatial 
patterns of the diffuse Aβ deposits varied among 
disorders (c2 = 33.14, 12 DF, p < 0.001), a greater pro-
portion of brain regions in AD exhibiting regularly 
distributed clusters compared with the other dis-
orders. Sixth, there were no significant differences 
among disorders in the proportions of regions exhib-
iting a regular pattern of clustering in which the dif-
fuse (c2 = 4.23, 4 DF, p < 0.05), primitive (c2 = 2.41, 
4 DF, p < 0.05), and classic (c2 = 6.18, 4 DF, p < 0.05) 
deposit clusters were in the range 400-800 mm.
A  comparison of mean cluster sizes of the Aβ 
deposit in each disorder is shown in Figure 5. The 
data suggest: (1) a  significant difference in cluster 
size of the diffuse deposits (F = 6.00, p < 0.001), 
cluster sizes being significantly smaller in CTE than 
in CBD, DLB and DS, (2) a  significant difference in 
the cluster size of the primitive deposits (F = 3.85, 
p < 0.01), cluster sizes being significantly less in CTE 
compared with AD and DS, and (3) no significant 
differences in the cluster size of the classic deposits 
among disorders (F = 1.44, p > 0.05). 
Discussion
A  degree of intra-and inter-observer variabili-
ty in the counts of Aβ deposits was detected, the 
inter-observer variability being consistently greater 
than intra-observer variability. The degree of con-
sistency detected was comparable to that previ-
ously reported for counting NFT but superior to that 
when estimating surviving neuronal perikarya or 
the degree of vacuolation in fronto-temporal lobar 
degeneration (FTLD) [8]. In neither case did the vari-
ations in counts alter conclusions regarding the spa-
tial pattern of the Aβ deposits.
The Aβ deposits commonly exhibited two types 
of spatial pattern: (1) regularly distributed clusters of 
deposits 200-6400 µm in diameter parallel to the tis-
sue boundary or (2) significantly larger aggregations of 
deposits; a single cluster often occupying a large area 
of a gyrus or sector of HC. These results are similar to 
those reported previously in AD and other disorders [5]. 
Regular distributed clusters of Aβ deposits along 
the cortex suggests a  spatial relationship with the 
neuro-anatomical pathways, especially the cortico- 
cortical pathways [4]. Hence, the cells of origin of the 
cortico-cortical projections are clustered and occur 
in bands which are distributed along the cortex. 
The individual bands of cells vary in width in the 
range 400-500 µm up to 800-1000 µm, depending 
on the cortical region [23]. In a  proportion of gyri 
studied in all disorders, the estimated widths of 
the clusters of Aβ deposits were within this predict-
ed size range [37]. In the remaining brain regions, 
clusters of Aβ deposits were significantly larger than 
1000 µm. Variation in mean size of the Aβ depos-
it clusters may depend on disease stage [14,15]. 
Hence, at an early stage, Aβ deposits may aggregate 
in smaller clusters associated with specific cortical 
columns, subsequent Aβ formation resulting in more 
of the column being affected. Ultimately, the coales-
cence of the original clusters results in the larger 
aggregations or more continuous distribution of 
deposits observed in several regions and disorders.
The observed spatial pattern of the Aβ deposit 
clusters may be a consequence of the hypothesized 
‘prion-like’ spread of Aβ among regions via neuro-an-
atomical pathways [20,43]. First, the spatial pat-
terns of the Aβ deposits are similar to those of PrPsc 
deposits in CJD [7]. Second, in a significant number 
of regions, regularly distributed clusters of Aβ depos-
its, 400-800 µm in diameter were present; within 
the predicted size range of the cell columns asso-
ciated of the cortico-cortical pathways [16,23,24]. 
Third, anatomically connected regions exhibited 
similar regularly distributed clusters of Aβ deposits, 
e.g., in the adjacent gyri LOT and PHG connected by 
cortical U-fibers. Fourth, virtually all patients with DS 
develop Aβ deposits within the brain if they survive 
into their thirties [30], with particular accumulations 
of deposits observed between the ages of 30 and 
50 years [27]. Cluster sizes of the primitive and clas-
sic Aβ deposits in the DS cases increased with age to 
a maximum in patients aged 45 to 55 and 60 years 
respectively, declining in size in the oldest patients 
suggesting growth in size of Aβ deposit clusters at 
least over part of the age range. 
Differences in cluster size of Aβ deposits were 
also observed among disorders, most notably in 
CTE which exhibited the smallest-sized clusters of 
diffuse and primitive deposits. Small cluster size in 
CTE could be attributable to: (1) lower densities of Aβ 
deposits overall compared with the other disorders, 
(2) differences in the vulnerability of anatomical 
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pathways to the spread of Aβ, a more selective group 
of neurons being compromised, or (3) differences in 
the timing and rate of spread of Aβ along neuroana-
tomical connections, ADNC developing later in CTE 
compared with the other disorders. Aβ deposits in 
the form of diffuse and NP have been recorded in 
52% and 36% of CTE cases respectively, a frequency 
which increased with the stage of the disease [42], 
which lends support to the third hypothesis. By 
contrast, the classic Aβ deposits in CTE are similar 
in size to those of the other disorders which may 
result from specific damage to cerebral microvessels 
caused by head trauma.
In conclusion, the spatial patterns of the diffuse, 
primitive, and classic Aβ deposits show considerable 
similarities in the five disorders studied consistent 
with the neuro-anatomical spread of Aβ as a common 
process regardless of clinical or pathological setting. 
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